Nuvectis Pharma, Inc. financial data

Symbol
NVCT on Nasdaq
Location
Fort Lee, NJ
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 11 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 282% % 1.6%
Debt-to-equity 55% % -2.4%
Return On Equity -132% % 18%
Return On Assets -85% % 17%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 26,491,702 shares
Common Stock, Shares, Outstanding 25,676,798 shares 32%
Entity Public Float $100,000,000 USD 100%
Weighted Average Number of Shares Outstanding, Basic 21,812,716 shares 27%
Weighted Average Number of Shares Outstanding, Diluted 21,812,716 shares 27%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $18,153,000 USD 41%
General and Administrative Expense $9,421,000 USD 36%
Operating Income (Loss) $27,574,000 USD -39%
Net Income (Loss) Attributable to Parent $26,442,000 USD -39%
Earnings Per Share, Basic -1.32 USD/shares -19%
Earnings Per Share, Diluted -1.32 USD/shares -19%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $31,634,000 USD 71%
Other Assets, Current $75,000 USD 1.4%
Assets, Current $31,709,000 USD 70%
Assets $31,709,000 USD 70%
Accounts Payable, Current $6,274,000 USD 151%
Employee-related Liabilities, Current $6,907,000 USD 24%
Accrued Liabilities, Current $115,000 USD -86%
Liabilities, Current $13,296,000 USD 49%
Liabilities $13,296,000 USD 49%
Retained Earnings (Accumulated Deficit) $99,687,000 USD -36%
Stockholders' Equity Attributable to Parent $18,413,000 USD 90%
Liabilities and Equity $31,709,000 USD 70%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $4,174,000 USD 4.2%
Net Cash Provided by (Used in) Financing Activities $15,505,000 USD 230%
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 60,000,000 shares 0%
Common Stock, Shares, Issued 25,676,798 shares 32%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $31,634,000 USD 71%
Deferred Tax Assets, Valuation Allowance $26,576,000 USD 36%
Deferred Tax Assets, Gross $26,576,000 USD 36%
Deferred Tax Assets, Operating Loss Carryforwards $15,132,000 USD 30%
Additional Paid in Capital $118,100,000 USD 42%
Deferred Tax Assets, Net of Valuation Allowance $0 USD